LV12574A - Aza cyclohexapeptide compounds - Google Patents

Aza cyclohexapeptide compounds

Info

Publication number
LV12574A
LV12574A LV000119A LV000119A LV12574A LV 12574 A LV12574 A LV 12574A LV 000119 A LV000119 A LV 000119A LV 000119 A LV000119 A LV 000119A LV 12574 A LV12574 A LV 12574A
Authority
LV
Latvia
Prior art keywords
compounds
useful
species
treatment
present
Prior art date
Application number
LV000119A
Other versions
LV12574B (en
Inventor
Frances Aileen Bouffard
James M Balkovec
Regina M Black
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21867140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of LV12574A publication Critical patent/LV12574A/en
Publication of LV12574B publication Critical patent/LV12574B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/27—Cyclic peptide or cyclic protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Vapour Deposition (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention is directed to certain aza cyclophexapeptide compounds having given general structure formula. These compounds are characterised in having a nitrogen attached to the cyclohexapeptide ring at the 5-carbon of the 4-hydroxy ornithine component. The compounds of the present invention are generally obtained as mixtures of stereoisomeric forms in which one form usually predominates. The compounds described, their pharmaceutically acceptable salts and acid addition salts are useful as an antibiotic, especially as an antifungal agent or as an antiprotozoal agent. As antifungal agents they are useful for the control of both filamentous fungi and yeasts. They are especially adaptable to be employed for the treatment of mycotic infections caused by Candida species, Cryptococcus species and Aspergillus species. They are also useful for the treatment and/or prevention of Pneumocystis carnii pneumonia to which immune-compromised patients are especially susceptible.
LVP-00-119A 1993-03-16 2000-09-07 Aza cyclohexapeptide compounds LV12574B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/032,847 US5378804A (en) 1993-03-16 1993-03-16 Aza cyclohexapeptide compounds

Publications (2)

Publication Number Publication Date
LV12574A true LV12574A (en) 2000-11-20
LV12574B LV12574B (en) 2001-04-20

Family

ID=21867140

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-00-119A LV12574B (en) 1993-03-16 2000-09-07 Aza cyclohexapeptide compounds

Country Status (33)

Country Link
US (3) US5378804A (en)
EP (1) EP0620232B1 (en)
JP (1) JP2568474B2 (en)
KR (1) KR100329693B1 (en)
CN (1) CN1098274C (en)
AT (1) ATE186736T1 (en)
AU (1) AU668804B2 (en)
BG (1) BG63047B1 (en)
BR (2) BR9406009A (en)
CA (1) CA2118757C (en)
CZ (1) CZ286235B6 (en)
DE (2) DE10299013I2 (en)
DK (1) DK0620232T3 (en)
ES (1) ES2139043T3 (en)
FI (1) FI109542B (en)
GR (1) GR3031872T3 (en)
HK (1) HK1008674A1 (en)
HR (1) HRP940161B1 (en)
HU (2) HU217614B (en)
IL (1) IL108892A (en)
LU (1) LU90875I2 (en)
LV (1) LV12574B (en)
NL (1) NL300076I2 (en)
NO (2) NO318372B1 (en)
NZ (1) NZ263360A (en)
PL (1) PL179261B1 (en)
RO (1) RO113246B1 (en)
RU (1) RU2122548C1 (en)
SI (1) SI9420013B (en)
SK (1) SK282527B6 (en)
UA (1) UA59329C2 (en)
WO (1) WO1994021677A1 (en)
ZA (1) ZA941807B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874403A (en) * 1992-10-15 1999-02-23 Merck & Co., Inc. Amino acid conjugates of cyclohexapeptidyl amines
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5948753A (en) * 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
JP3118466B2 (en) * 1994-08-23 2000-12-18 メルク エンド カンパニー インコーポレーテッド Improved process for producing side chain derivatives of cyclohexapeptidyl lipopeptide
US5516757A (en) * 1994-09-16 1996-05-14 Merck & Co., Inc. Semi-synthetic lipopeptides, compositions containing said lipopeptides, and methods of use
US5514651A (en) * 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
JP3657989B2 (en) * 1994-09-16 2005-06-08 メルク エンド カンパニー インコーポレーテッド Azacyclohexapeptide compound
US5516756A (en) * 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
AU691743B2 (en) * 1995-01-26 1998-05-21 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5552521A (en) * 1995-02-10 1996-09-03 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
EP0862579A1 (en) * 1995-11-09 1998-09-09 Merck & Co., Inc. Cyclohexapeptidyl bisamine compound, compositions containing said compound and methods of use
US5952300A (en) * 1996-04-19 1999-09-14 Merck & Co., Inc. Antifungal compositions
AR006598A1 (en) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "ANTI-FUNGOUS COMPOSITIONS, ITS USE IN THE MANUFACTURE OF MEDICINES AND A PROCEDURE FOR THE PREPARATION"
HRP970318B1 (en) * 1996-06-14 2002-06-30 Merck & Co Inc A process for preparing certain aza cyclohexapeptides
USRE38984E1 (en) * 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
EA002469B1 (en) * 1996-09-12 2002-06-27 Мерк Энд Ко., Инк. Method for treating fungal infections
US5854212A (en) * 1996-10-23 1998-12-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compound, compositions containing said compound and methods of use
US5936062A (en) * 1997-06-12 1999-08-10 Merck & Co., Inc. Process for preparing certain aza cyclohexapeptides
EP1204677B1 (en) * 1999-07-27 2008-12-03 Aventis Pharma Deutschland GmbH Cyclohexapeptide compounds, process for their production and their use as a pharmaceutical
AR035808A1 (en) * 2001-04-12 2004-07-14 Merck & Co Inc DEHYDRATION PROCESS ABLE TO MINIMIZE THE EPIMERIZATION OF A HYDROXYL GROUP BY CERTAIN EQUINOCANDINES
JP4625637B2 (en) 2002-02-22 2011-02-02 シャイア エルエルシー Active substance delivery system and method for protecting and administering an active substance
US7214768B2 (en) * 2002-04-08 2007-05-08 Merck & Co., Inc. Echinocandin process
DE602004010915T2 (en) 2003-07-22 2008-12-11 Theravance, Inc., South San Francisco USE OF AN ANTIMYCOTIC ECHINOCANDIN AGENT COMBINED WITH AN ANTIBACTERIAL GLYCOPEPTIDE AGENT
CN1950396A (en) * 2004-02-24 2007-04-18 联邦科学技术研究组织 Antifungal peptides
EP1785432A1 (en) * 2005-11-15 2007-05-16 Sandoz AG Process and intermediates for the synthesis of caspofungin.
KR101536781B1 (en) 2006-07-26 2015-07-14 산도즈 아게 Caspofungin formulations
TW200826957A (en) * 2006-10-16 2008-07-01 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Purification processes for echinocandin-type compounds
WO2009002481A1 (en) 2007-06-26 2008-12-31 Merck & Co., Inc. Lyophilized anti-fungal composition
US20090075870A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched caspofungin
WO2009142761A1 (en) * 2008-05-21 2009-11-26 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Caspofungin bo free of caspofungin co
US8048853B2 (en) * 2008-06-13 2011-11-01 Xellia Pharmaceuticals Aps Process for preparing pharmaceutical compound and intermediates thereof
WO2010008493A2 (en) * 2008-06-25 2010-01-21 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Processes for preparing high purity aza cyclohexapeptides
KR20110011704A (en) * 2008-06-25 2011-02-08 테바 기오기스제르갸르 자르트쾨렌 뮈쾨되 레스즈베니타르사사그 Caspofungin free of caspofungin impurity a
WO2010064219A1 (en) 2008-12-04 2010-06-10 Ranbaxy Laboratories Limited Process for the preparation of a novel intermediate for caspofungin
TW201024322A (en) * 2008-12-31 2010-07-01 Chunghwa Chemical Synthesis & Biotech Co Ltd Preparation method for nitrogen containing heterocyclic hexapeptide with high conversion rate
WO2010108637A1 (en) 2009-03-27 2010-09-30 Axellia Pharmaceuticals Aps Crystalline compound
CN101602795B (en) * 2009-07-20 2011-12-21 中国人民解放军第二军医大学 Cyclohexalipopeptide amine antifungal compound, salts and preparation method thereof
EP2463293A4 (en) * 2009-08-06 2013-06-05 Shanghai Techwell Biopharm Co Azacyclohexapeptide or its pharmaceutical acceptable salt, preparing method and use thereof
US8751760B2 (en) * 2009-10-01 2014-06-10 Dell Products L.P. Systems and methods for power state transitioning in an information handling system
CN101792486A (en) * 2010-04-12 2010-08-04 浙江海正药业股份有限公司 Method for combining caspofungin acetate
CN102219832B (en) 2010-04-15 2013-08-21 上海天伟生物制药有限公司 Purifying method of azacyclohexapeptides or salts thereof
WO2012038371A1 (en) 2010-09-20 2012-03-29 Xellia Pharmaceuticals Aps Caspofungin composition
JP6000254B2 (en) * 2010-09-29 2016-09-28 上海天偉生物制薬有限公司 Method for purifying cyclic lipopeptide compound or salt thereof
AU2011307733B2 (en) * 2010-09-30 2015-03-26 Shanghai Techwell Biopharmaceutical Co., Ltd. Method for purifying cyclic lipopeptide or salt thereof
CN102367269B (en) 2010-11-10 2013-11-06 上海天伟生物制药有限公司 Caspofungin analogue, its preparation method and application
CN102367267B (en) 2010-11-10 2013-09-04 上海天伟生物制药有限公司 Preparation method of caspofungin
CN102367268B (en) 2010-11-10 2013-11-06 上海天伟生物制药有限公司 Caspofungin analogue and use thereof
KR101331984B1 (en) 2010-12-09 2013-11-25 종근당바이오 주식회사 Method of preparing a caspofungin and new intermediates thereof
US20140005355A1 (en) * 2011-01-03 2014-01-02 Biocon Limited Process for preparation of caspofungin acetate and intermediates
CN102618606B (en) * 2011-01-30 2014-09-10 浙江海正药业股份有限公司 Echinocandin biotransformation method
HUE036778T2 (en) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Antifungal agents and uses thereof
CN102746384B (en) 2011-04-22 2016-01-20 上海天伟生物制药有限公司 A kind of highly purified Caspofungin or its salt and its production and use
BR112013026868A2 (en) 2011-04-28 2016-09-06 Unitris Biopharma Co Ltd intermediate for caspofungin synthesis and method for its preparation
CN104507309B (en) 2012-03-19 2017-05-03 奇达拉治疗公司 Dosing regimens for echinocandin class compounds
CA2888625A1 (en) * 2012-11-20 2014-05-30 Fresenius Kabi Usa, Llc Caspofungin acetate formulations
CN105481952B (en) * 2014-12-24 2020-12-29 上海天伟生物制药有限公司 Composition containing nitrogen heterocyclic hexapeptide precursor and preparation method and application thereof
US9675659B2 (en) 2015-08-21 2017-06-13 Trilogy Therapeutics, Inc. Methods of treating lung infection with caspofungin
CN108883152A (en) 2016-01-08 2018-11-23 奇达拉治疗公司 The method for preventing and treating carinti infections
CN109154603A (en) 2016-03-16 2019-01-04 奇达拉治疗公司 For treating the dosage regimen of fungal infection
WO2017185030A1 (en) * 2016-04-22 2017-10-26 Fresenius Kabi Usa, Llc Caspofungin formulation with low impurities
EP3651801A4 (en) 2017-07-12 2021-04-07 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2019157453A1 (en) 2018-02-12 2019-08-15 Trilogy Therapeutics, Inc. Caspofungin compositions for inhalation
EP3620462A1 (en) 2018-09-04 2020-03-11 Xellia Pharmaceuticals ApS Process for the preparation of caspofungin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE851310A (en) * 1976-02-12 1977-08-10 Sandoz Sa NEW DERIVATIVES OF TETRAHYDRO-EQUINOCANDIN B
DE2704030A1 (en) * 1976-02-12 1977-08-18 Sandoz Ag NEW ORGANIC COMPOUNDS, THEIR PRODUCTION AND USE
DE2742435A1 (en) * 1976-09-28 1978-04-06 Sandoz Ag AMINO ALKYL ETHER OF THE PEPTIDES TETRAHYDRO- SL 7810 / F-II, S 31794 / F-1, ACULEACIN A AND TETRAHYDROECHINOCANDIN B, THEIR USE AND PRODUCTION
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4320053A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912D nucleus
EP0030844A1 (en) * 1979-12-13 1981-06-24 Eli Lilly And Company Recovery process for A-30912 antibiotics
US4287120A (en) * 1979-12-13 1981-09-01 Eli Lilly And Company Derivatives of S31794/F-1 nucleus
US4293485A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of S31794/F-1 nucleus
DE3030554A1 (en) * 1980-08-13 1982-03-25 Chemische Werke Hüls AG, 4370 Marl BURNING PAINTS
US4931352A (en) * 1987-10-07 1990-06-05 Merck & Co., Inc. Antifungal fermentation product
DK173802B1 (en) * 1988-09-12 2001-11-05 Merck & Co Inc Preparation for the treatment of Pneumocystis carinii infections and use of a cyclohexapeptide for the preparation of a drug against Pneumocystis carinii infections
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
US5194377A (en) * 1989-06-30 1993-03-16 Merck & Co., Inc. Antibiotic agent
NZ234225A (en) * 1989-06-30 1993-09-27 Merck & Co Inc Antibiotic from zalerion arboricola and its use as an antifungal agent and antipneumocystis agent
US5021341A (en) * 1990-03-12 1991-06-04 Merck & Co., Inc. Antibiotic agent produced by the cultivation of Zalerion microorganism in the presence of mannitol
GB8925593D0 (en) * 1989-11-13 1990-01-04 Fujisawa Pharmaceutical Co Fr901379 substance and preparation thereof
US5159059A (en) * 1990-05-29 1992-10-27 Merck & Co., Inc. Process for reduction of certain cyclohexapeptide compounds
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof
US5378804A (en) * 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516757A (en) * 1994-09-16 1996-05-14 Merck & Co., Inc. Semi-synthetic lipopeptides, compositions containing said lipopeptides, and methods of use
US5516756A (en) * 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds

Also Published As

Publication number Publication date
BG63047B1 (en) 2001-02-28
ZA941807B (en) 1994-10-13
HRP940161B1 (en) 2001-04-30
DE10299013I1 (en) 2003-01-23
PL310634A1 (en) 1995-12-27
SK282527B6 (en) 2002-10-08
UA59329C2 (en) 2003-09-15
US5792746A (en) 1998-08-11
NO953648L (en) 1995-11-15
RO113246B1 (en) 1998-05-29
JPH06321986A (en) 1994-11-22
IL108892A0 (en) 1994-06-24
HU9502703D0 (en) 1995-11-28
CA2118757C (en) 2002-05-14
NL300076I1 (en) 2002-03-01
HU211890A9 (en) 1995-12-28
US5378804A (en) 1995-01-03
NL300076I2 (en) 2002-04-02
PL179261B1 (en) 2000-08-31
HU217614B (en) 2000-03-28
GR3031872T3 (en) 2000-02-29
KR960701092A (en) 1996-02-24
ES2139043T3 (en) 2000-02-01
HK1008674A1 (en) 1999-05-14
SK113695A3 (en) 1996-02-07
LU90875I2 (en) 2002-03-04
EP0620232B1 (en) 1999-11-17
DE69421639T2 (en) 2000-06-08
SI9420013B (en) 2002-12-31
EP0620232A1 (en) 1994-10-19
US5514650A (en) 1996-05-07
BG99999A (en) 1996-04-30
HUT73496A (en) 1996-08-28
DK0620232T3 (en) 2000-03-13
FI954327A (en) 1995-09-14
AU5783294A (en) 1994-09-22
NZ263360A (en) 1997-08-22
CZ235895A3 (en) 1996-02-14
BR1100273A (en) 1999-10-13
DE10299013I2 (en) 2009-11-19
AU668804B2 (en) 1996-05-16
FI109542B (en) 2002-08-30
KR100329693B1 (en) 2002-08-14
SI9420013A (en) 1996-08-31
CA2118757A1 (en) 1994-09-17
NO2005020I2 (en) 2008-12-01
HRP940161A2 (en) 1996-08-31
NO953648D0 (en) 1995-09-15
BR9406009A (en) 1995-12-26
CZ286235B6 (en) 2000-02-16
LV12574B (en) 2001-04-20
RU2122548C1 (en) 1998-11-27
FI954327A0 (en) 1995-09-14
WO1994021677A1 (en) 1994-09-29
NO318372B1 (en) 2005-03-14
NO2005020I1 (en) 2005-09-13
CN1098274C (en) 2003-01-08
IL108892A (en) 1998-07-15
JP2568474B2 (en) 1997-01-08
DE69421639D1 (en) 1999-12-23
CN1119441A (en) 1996-03-27
ATE186736T1 (en) 1999-12-15

Similar Documents

Publication Publication Date Title
LV12574A (en) Aza cyclohexapeptide compounds
Oakley et al. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
GB2247018B (en) Hydrogenated rapamycin derivatives
TW377349B (en) Tetrahydrofuran antifungals
UA42699C2 (en) Benzoxazinones, pharmaceutical composition (variants), combination of compounds (variants), method for inhibition of hiv reverse transcriptase, method for preventing or treating hiv infections
GR3034366T3 (en) Cyclic antimicrobial peptides and preparation thereof.
SG42920A1 (en) Tri-substituted tetrahydrofuran antifungals
WO2003005954B1 (en) Methods and materials for the treatment of testosterone deficiency in men
Kan et al. Efficacies of four antifungal agents in experimental murine sporotrichosis
ATE178798T1 (en) USE BEFORE SIMPLE OR CONJUGATED DEXTRAN IN THE PRODUCTION OF A MEDICATION TO PREVENT OR REDUCE THE RISK OF A BACTERIAL PATHOGENIC INFECTION
NZ234225A (en) Antibiotic from zalerion arboricola and its use as an antifungal agent and antipneumocystis agent
DE3475714D1 (en) Griseolic acid derivatives, and their use
HUP9901686A2 (en) Fungicidal mixtures
UA39171C2 (en) Seed of plants, method to protect the seed against fungal diseases and fungicidal composition to protect seed against the fungal diseases
IT1261199B (en) FUNGICIDAL COMPOSITIONS TO COMBAT PHYTOPATHOGENIC MUSHROOMS.
Van Cutsem et al. In-vitro and in-vivo models to study the activity of antifungals against Aspergillus
EP0929217A4 (en) Sordarin derivatives
Mikami et al. Synergistic interaction of miconazole and fluconazole at sub‐MIC level on Candida albicans: Synergistische Wirkung von Miconazol und Fluconazol in subinhibitorischen Konzentrationen auf Candida albicans
WO2002055022A3 (en) Active metabolite of antifungal compound
Morrison et al. Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis
Wild Fungicidal activity of potassium sorbate against Penicillium digitatum as affected by thiabendazole and dip temperature
Kobasa et al. Aztreonam, cefoperazone, and gentamicin in the treatment of experimental Enterobacter aerogenes endocarditis in rabbits
BE900186A (en) SYNERGISTIC FUNGICIDE COMPOSITIONS.
IL97040A (en) Antibiotic, deoxymulundocandin, a process for its production and pharmaceutical compositions containing it
Kovacicova et al. Persistent fungemia-Risk factors And outcome in 40 episodes